If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
166
results.
Updated on
11/10/2026 [06:54:00]
Results 75 to 100 of 166
Absstract of: US20260272337A1
The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Absstract of: US20260279537A1
Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.
Absstract of: US20260273184A1
Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.
Absstract of: US20260279578A1
Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein. Color fundus imaging data is received for an eye being evaluated for DR. A metric is generated using the color fundus imaging data, the metric indicating a probability that a score for the DR severity in the eye falls within a selected range.
Absstract of: US20260275292A1
A maturation medium and a method for maturing an early embryonic human heart organoid into a mature human heart organoid are provided herein. The maturation medium includes a cell growth medium containing a medium supplement including one or more fatty acid, triiodothyronine (T3) growth hormone, insulin, one or more antioxidant, a sugar, and carnitine; one or more additional fatty acid; an additional carnitine or creatine; and an additional T3 growth hormone. The maturation medium may further include one or more of an additional sugar, an additional antioxidant, and a growth factor. The method includes contacting an early embryonic human heart organoid with one or more maturation medium to produce a mature human heart organoid.
Absstract of: US20260275287A1
An object of the present invention is to provide a solution for thawing that can maintain or improve the cytotoxic activity of highly active NK cells and the like after thawing. A solution for suspending cells for administration to humans, which satisfies the following criteria: (1) containing potassium ion, (2) having a pH of 4.9 or higher, (3) not containing chloride ions at a concentration of 135 mEq/L or higher, (4) not containing glucose at a concentration of 5.55 mM or higher, (5) not containing calcium ions at a concentration of 0.423 mM or higher, (6) having an osmolarity of 200 to 396 mOsm, and (7) containing any organic acid(s) selected from the group consisting of succinic acid, malic acid, lactic acid, citric acid, and acetic acid.
Absstract of: US20260273059A1
The present disclosure is directed to methods, compositions and devices capable of avoiding foreign body responses to implanted material. This technology utilizes polymer encapsulated engineered cells that produce natural, cell-generated cytokines to elicit a tailored immune response to implanted materials for applications in diabetes, immune tolerance, and organ transplantation.
Absstract of: US20260272335A1
A customized wearable saliva biosensor system for continuous, real-time, in-situ monitoring of biochemical markers in human saliva. The system integrates a multi-gate organic electrochemical transistor biosensor employing an organic semiconductor channel with enzyme-functionalized gate electrodes, a compact wireless integrated circuit with Bluetooth data transmission, a power subsystem optionally incorporating piezoelectric and/or triboelectric nanogenerators, and a custom-fitted wearable substrate fabricated from a three-dimensional scan of the user's dental anatomy. The system is positioned within the oral cavity in proximity to the sublingual glands for direct detection of fresh saliva at the point of secretion. A differential measurement architecture comparing an enzyme gate to a control gate provides selective, real-time detection of target biomarkers including glucose, lactate, and uric acid. Measured data is wirelessly transmitted to a companion mobile application for display to the user.
Absstract of: WO2026193167A1
The present disclosure provides modified cells for use in cell therapies to treat diabetes, as well as methods for preparing such cells. More specifically, the present disclosure provides genetically modified cells that reduce the production of extracellular matrix following implantation and/or express a novel peptide that targets the cells for destruction without impacting the subject's native cells.
Absstract of: WO2026193386A1
Systems and methods for estimating and tracking blood glucose levels are provided. A method includes receiving, from a sensor, a plurality of photoplethysmography (PPG) signals, deriving an oxygenated hemoglobin concentration signal and a deoxygenated hemoglobin concentration signal from the PPG signals, determining a phase relationship between the oxygenated hemoglobin concentration signal and the deoxygenated hemoglobin concentration signal, generating a glycemic pointer based at least in part on the phase relationship, and generating a first blood glucose level based on the glycemic pointer.
Absstract of: US20260272353A1
Systems and methods are described for monitoring blood glucose when driving. The methods may include receiving blood glucose input for a user over a time period, detecting one or more driving events associated with the user over the time period, correlating the blood glucose input with the one or more driving events; determining, based on the correlation, at least one pattern indicating a blood glucose status for the user, generating, based on the blood glucose status and a repository of user data, at least one insight or trend corresponding to the user, and causing presentation of the at least one insight or trend.
Absstract of: EP4806508A2
A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
Absstract of: EP4806353A2
0001 Methods, systems, and devices for continuous glucose monitoring. More particularly, the methods, systems, and devices describe a working electrode with a GOx sensor and a background electrode in which the background electrode has no GOx sensor. The system may then compare the first signal and the second signal to detect ingestion of a medication by the user. The system may generate a sensor glucose value based on the comparison.
Absstract of: EP4806354A2
0001 The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: EP4807357A2
A method of making a nanoporous layer comprises providing a liquid composition comprising a surfactant and metal ions, adding a reducing agent to cause reduction of at least part of the metal ions to form nanoparticles, removing the surfactant to form a second colloid, adjusting a concentration of the nanoparticles to provide a colloid composition, dispensing the colloid composition over a substrate, and subjecting the dispensed colloid composition to drying to form the nanoporous layer.
Absstract of: EP4806351A2
0001 Embodiments of the invention provide compositions useful in implantable devices such as analyte sensors as well as methods for making and using such compositions and devices. In typical embodiments of the invention, the device is a glucose sensor comprising a polymeric composition disposed on a flexible assembly within the sensor that includes amounts of one or more immunosuppressant agents designed to provide such sensors with improved material properties such as enhanced biocompatibility.
Absstract of: WO2026184157A1
The present application relates to the technical field of computers, and specifically relates to a sensor, a measurement apparatus, a physiological parameter measurement method, and an electronic device. The sensor may be provided with at least a first working electrode and a second working electrode that are configured to acquire monitoring data. A first membrane layer attached to the surface of an enzyme layer of the first working electrode and a second membrane layer attached to the surface of an enzyme layer of the second working electrode may have different parameters, for example, the thickness of the second membrane layer is greater than the thickness of the first membrane layer, or the second membrane layer comprises a limiting layer, a protective layer formed of a soluble material attached to the surface of the limiting layer, etc., such that a first duration required for glucose to permeate through the first membrane layer is less than a second duration required for glucose to permeate through the second membrane layer, thereby enabling the second working electrode to be activated after the first working electrode has been used for a preset duration. In this way, the service life of the sensor, and that of the measurement apparatus, the electronic device, etc., using the sensor can be prolonged, which is beneficial for improving the user experience.
Absstract of: WO2026184355A1
The present application relates to a method for online monitoring of vital sign parameters of a host and a multi-working-electrode system, which can improve the accuracy of glucose monitoring. The method comprises: using a first working electrode to acquire a first vital sign parameter of a host; using a second working electrode to acquire a second vital sign parameter of the host; and acquiring, on the basis of the first vital sign parameter and the second vital sign parameter, a target glucose concentration of the host. The first working electrode and the second working electrode are arranged on the same substrate, and can acquire the first vital sign parameter and the second vital sign parameter, respectively, at different depths of the host's tissue independently of each other. The two working electrodes can effectively determine analyte concentrations at different depths, which, combined with the vital sign parameters generated by the different working electrodes, can comprehensively provide more reliable continuous monitoring results, thereby improving the accuracy of monitoring.
Absstract of: AU2025232283A1
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Absstract of: WO2026187690A1
The present disclosure generally relates to cell therapies and related methods, kits, assays, tests and devices for treatment of diabetes, including Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D), and other conditions characterized by insulin deficiency.
Absstract of: WO2026186968A1
The present invention relates to a composition for restoring pancreatic beta-cell function, the composition comprising intestinal organoid-derived exosomes. The intestinal organoid-derived exosomes according to the present invention have the effects of improving pancreatic-related markers and inflammation-related factors in a beta-cell damage model treated with palmitic acid, reducing the expression of oxidative stress-related factors, and restoring insulin secretion ability, and thus can be effectively used in the treatment of various diseases related to pancreatic beta-cell dysfunction, including diabetes.
Absstract of: WO2026187966A1
A wearable smart insole for a user having foot having a planter arch and a medial plantar artery (MPA) along the plantar arch is provided. The insole has at least one optical sensor disposed in the insole along the MPA, a power handling circuit, an energy storage module operatively coupled with the power handing circuit to provide power to the optical sensor. The optical sensor is disposed along the MPA. in the insole and provides a signal for obtaining heart rate data, blood oxygen saturation data and blood glucose measurements. Two optical sensors may be provided along the MPA to provide signals for calculating blood pressure. A third optical sensor may be provided along the lateral plantar artery to provide signals to detect diabetes or arterial disease.
Absstract of: WO2026188217A1
Described herein are compositions comprising Apolipoprotein E3 with the Christchurch mutation (e.g., R136S), or nucleic acids encoding the same, and methods of use thereof in disorders associated with aberrant angiogenesis, e.g., ocular neovascularization such as in wet age-related macular degeneration and diabetic retinopathy, or solid tumors, or bone diseases, e.g., osteoporosis including diabetic osteoporosis, or osteogenesis imperfecta.
Absstract of: WO2026187363A1
A method of multi-analyte analysis includes applying an electrical test sequence to a sample applied to a reagent in an electrochemical sensing device, generating a measurement of a primary analyte in the sample based on a response to the electrical test sequence, generating a classification of a secondary' analyte in the sample based on a least one feature extracted from the response to the electrical test sequence provided to a machine-learning model, the second analyte being different titan the first analyte, and generating at least one output corresponding to the measurement of the primary' analyte and the classification of the secondary analyte. Particular analytes of interest include glucose measurement and ketone classification.
Nº publicación: US20260269465A1 10/09/2026
Applicant:
INSULET CORP [US]
Insulet Corporation
Absstract of: US20260269465A1
0000 A medical device such as an automated medicament delivery device for automated administration of medicament to a user-body or an analyte sensor such as a continuous glucose monitor for detecting analyte levels in a user-body are disclosed. The automated medicament delivery device includes an antenna, a communication chip, and a gain control circuit. The communication chip configured for operation of the antenna in at least two selectable modes including a high-gain mode and a low-gain mode. The high-gain mode and the low-gain mode of the antenna at least partially based on a state of a gain control circuit operatively coupling the communication chip with the antenna. The antenna, utilizing the gain control circuit, operable in the low-gain mode during performance of a pairing operation with a separate device and operable in the high-gain mode during ongoing external communication.
BOPI
Electronic site
